U.S. District Judge Barbara Jones in Manhattan today ruled that drug applications by Sandoz and Mylan for generic versions of TEVA’s patented drug, Copaxone, a pharmaceutical treatment for multiple sclerosis medicine “infringe all of the asserted claims.”
Teva sued Basel, Switzerland-based Novartis and Cambridge, Massachusetts-based Momenta, saying that copies of Copaxone would infringe four patents that expire in 2014.
The Federal Judge has now ruled that the infringed claims are valid and enforceable.
Momenta, a further company attempting to bring a generic version of the product to market was not mentioned in the ruling.
The case is Teva Pharmaceuticals USA Inc. v. Sandoz Inc., 08-cv-07611, U.S. District Court, Southern District of New York (Manhattan).